<DOC>
	<DOCNO>NCT01289886</DOCNO>
	<brief_summary>The objective study determine safety tolerability determine Pharmacokinetic Pharmacodynamic ( PK/PD ) ascend single oral dose BR-A-657 healthy male subject .</brief_summary>
	<brief_title>Fimasartan ( BR-A-657 ) Single Oral Dose Healthy Subjects</brief_title>
	<detailed_description>BR-A-657 20 , 50 , 120 , 240 , 360 , 480mg placebo administer healthy male subject . Pharmacokinetic Pharmacodynamic ( PK/PD ) parameter monitor pre-specified time subject . PK parameter : Area Under Curve ( AUC ) , Cmax , half-life , etc . PD parameter : Aldosterone , Plasma renin activity , Angiotensin I , Angiotensin II Adverse event report .</detailed_description>
	<criteria>male 1855 year old Body Mass Index ( BMI ) 1929kg/m2 subject good health subject write informed consent subject multiple drug allergy allergy Angiotensin Receptor Blocker ( ARB ) subject medication affect drug absorption elimination within 30days . subject orthostatic hypotension &gt; 20mmHg decrease Systolic Blood Pressure ( SBP ) subject history neurologic , liver , renal , gastrointestinal , cardiovascular , psychological major disorder</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>January 2011</verification_date>
	<keyword>single-dose</keyword>
	<keyword>pharmacokinetic</keyword>
	<keyword>pharmacodynamic</keyword>
	<keyword>safety</keyword>
</DOC>